Market Overview

Biogen Volatile After Q3 Beat, Raised Guidance And Disappointing Phase 3 Study

Related BIIB
Benzinga's Bulls & Bears Of The Week: Bristol-Myers, GE, Target, Under Armour And More
Argus Downgrades Biogen On Trial Delays, Competition In MS, Alzheimer's Drugs
Tracking Jeffrey Ubben's ValueAct Portfolio - Q4 2017 Update (Seeking Alpha)

Biogen Inc (NASDAQ: BIIB) shares were trading higher by $10 at $275.81 in Wednesday's session. The Street is putting more emphasis on the Q3 beat and raised guidance as opposed to poor results from a Phase 3 study for Natalizumab.

After higher open, it rallied to $291.01 before reversing course. The ensuing decline took the issue beyond Tuesday's low ($264.58), reaching $262.45 before rebounding into the mid-$270 handle.

Posted-In: Technicals Intraday Update Movers Trading Ideas


Related Articles (BIIB)

View Comments and Join the Discussion!